Courts Must Analyze Claims as a Whole to Determine Whether Independent Claims That Lack Written Description Preclude Assertion of Dependent Claims

July 18, 2023

Reading Time : 2 min

The District Court for the District of New Jersey recently denied a defendant’s motion for summary judgment which sought to invalidate a dependent claim on preclusion grounds based on the PTAB’s invalidation of the related independent claim for lack of written description. Because the claims were not identical in scope when viewed as a whole, the district court found it could not assume the differences were immaterial. Factual issues, therefore, prevented application of preclusion.

In 2018, the PTAB held, inter alia, that independent claim 1 of plaintiff Indivior, Inc.’s patent was anticipated. The PTAB concluded that claim 1 was not entitled to a parent application’s priority date because there was no written description support for claim 1’s 40-60% polymeric matrix limitation. Thus, the relevant anticipatory reference was prior art to claim 1. In contrast, however, the PTAB concluded that the parent application did provide written description support for claim 8, which depended from claim 1, but claimed a specific value within the range. And because claim 8 was entitled to the benefit of its priority date, it was not anticipated by the asserted reference. The Federal Circuit affirmed.

In the district court litigation, Indivior asserted previously unchallenged claim 6 against defendant Alvogen Pine Brooks LLC. Claim 6 incorporated all limitations from claim 1—including the 40-60% polymeric matrix limitation—but further required a specific ratio between a different component and the polymeric matrix. Alvogen filed a motion for summary judgment, arguing that because claim 6 included the same 40-60% limitation as claim 1, it must be found to lack sufficient written description based on principles of claim preclusion.

The district court disagreed, reasoning that the written description requirement applies to patent claims in their entirety, not to individual limitations. Claim 6 included a limitation not found in claim 1. That added limitation was not considered in the PTAB’s determination, and the district court could not assume at the summary judgment stage that the differences between claim 1 and claim 6 were immaterial. It is not the case that when an independent claim lacks written description support all of its dependent claims necessarily lack written description support. Indeed, the PTAB (affirmed by the Federal Circuit) previously concluded that claim 8, which expressly narrowed claim 1’s range to a specific value, was adequately supported.

Thus, the questions of whether claim 6’s added ratio limitation necessarily narrowed the polymeric matrix range to less than 40-60% and whether the specification would support any such narrower range were factual questions the court could not to resolve at summary judgment.

The district court also found that the differences in the burdens of proof between the PTAB and district courts provide an alternative basis to deny summary judgment on preclusion grounds in this case, but noted that general rule would not apply under Federal Circuit precedent if the case involved the same claims challenged at the PTAB.

Practice Tip: When faced with a question of issue preclusion, be sure to analyze the claim as a whole to determine whether the identical relevant issue was in fact litigated in a previous case. Be prepared to explain why differences between an asserted claim and a previously invalidated claim are, or are not, material to the validity question at hand.

Indivior Inc. v. Alvogen Pine Brook LLC, No. 17-7106, 18-5285 (D.N.J June 26, 2023)

Share This Insight

Previous Entries

IP Newsflash

June 5, 2026

The Supreme Court unanimously held that for a complaint of induced infringement, a patent owner must allege that the accused infringer took affirmative, not passive, steps to encourage direct infringement. Thus, where a generic drug has a skinny label, to induce infringement of the carved-out patented use of the drug, the generic company must have taken steps that were designed to cause others to perform the patented use, not just steps that could cause such conduct.

...

Read More

IP Newsflash

May 07, 2026

The Northern District of Illinois granted a summary judgment motion of no invalidity based on indefiniteness because the qualitative terms like “sufficiently slow” and “desired period of time” were definite when viewed in light of the surrounding claim language and specification.

...

Read More

IP Newsflash

April 9, 2026

In the April 1, 2026 edition of the Official Gazette, the U.S. Patent and Trademark Office announced a new procedural framework that permits patent owners to submit a limited, early response to a request for ex parte reexamination.

...

Read More

IP Newsflash

March 12, 2026

The Northern District of Illinois recently dismissed a complaint without prejudice for failing to plausibly allege patent infringement. The court found that the allegations of direct infringement were insufficiently pled where the images of the accused product included in the complaint did not appear to show a particular necessary element of the claims.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.